In the past few years a large body of evidence has been accumulated indicating a possible central role of choksterol in the pathobiology of cancer. Alterations in the synthesis, uptake and intracellular content of cholesterol have been observed in a variety of experimental tumour models as well as in different types of human neoplasms (Anderson et al., 1981; Coleman and Lavietes, 1981; Yachnin et al., 1983; Dessi et al., ,b, 1994 .
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Choksterol perturbations also include change in lipoprotein profiles in plasma compartment. In particular, a definite decrease in high-density lipoprotein (HDL) klvels is a consistent finding in both experimental rat tumours and human neoplass (Dessi et at., 1991 (Dessi et at., ,b, 1994 despite the differences reported to exist between lipoprotein metabolism in rodents and humans (Dietschy et al., 1993) . In contrast, changes in other serm lipid parameters, such as total cholsterol and tnglyceride klvels, appear to vary and to be speces specific and dependent on the histological type or tumour grade (Dessi et al., 1991 (Dessi et al., ,b, 1994 . Therefore, it is possible that the mechanistic basis for the altered HDL levels is different from that responsible for the observed changes in other serum lipid parameters. Admittedly, HDLs play an important role in the transport of excess cholesterol from extrahepatic tisues to the liver for reutilisation or excretion into bile (reverse cholesterol transport). It is thus conceivable that the observed low levels of HDL-cholesterol may be related, at least in part, to a decrased choklsterol efflux to HDL as a consequence of increased utilisation and storage in actively proliferating tissues, such as neoplasms. However, since precursor prticles of HDL are thought to derive from lipolysis of triglyceride rich lipoproteins (Eisenberg, 1984) and since a signcnt positive correlation between plasma HDL cholesterol and lipoprotein lipase Correspondence: S Dessi Received 21 November 1994; revised 2 June 1995; accepted 7 June 1995 (LPL) activity in adipose tissue has also been reported (Eisnberg, 1984) , the possibility that low HDL cholesterol concentrations observed during tumour growth may be secondary to the decreased triglyceride clarance from plasna, as a result of LPL inhibition, must also be considered Tumour necrosis factor (rNF), a pleiotropic cytokine primarily produced by activated macrophages in response to invasve stimuli (Beutler and Cerami, 1988) , has been frequently reported as beng responsible for changes in lipid metaboism which occur in association with infections and tumours in a wide variety of species, including humans and rats (Feingold et al., 1987 (Feingold et al., , 1992 Harada et al., 1990) . TNF might affect plasm cholesterol, triglyceride and lipoprotein levels by both inhibition of adipose LPL activity and/or stimulation of hepatic lipogenesis (Feingold et al., 1992 (Feingold et al., , 1993 lipid metabolism in rats bearing ascites hepatoma Yoshida AH-130 has been previously investigated in our laboratories. This tumour causes in the host a rapid loss of body weight, associated with mared perturbations of both protein (Tessitore et al., 1987 and lipid metabolism . Increased synthesis and progressive accumulation of cholesterol were observed in AH-130 cells. During tumour growth, rats developed changes in serm lipid concentrations that included elevation of total cholesterol and triglycerides as well as a sharp reduction of HDL-cholesterol. Concurrently, the plasma lvels of TNF were elevated, while the activity of LPL in the white adipose tissue was decreased Carb6 et al., 1994 
Analytical procedures
To determine free and esterified cholesterol as well as triglyceride contents, total lipids were extracted as described above. The two cholesterol moietes were measured as directed by Bowman and Wolf (1962) , using cholesterol and cholesterol palmitate (Sigma, St Louis, MO, USA) as standards, while triglyceride content was evaluated by the method of Van Handel and Zilversmit (1968) , with triolein as the worling standard.
DNA content was measured by the method of Boer (1975) and protein that of Lowry et al. (1951) , using herring sperm DNA and bovine serum albumin as working standards IrePetively.
Cholsterol, triglyceride, free fatty acid and phospholipid concentrations in plasma and ascitic fluid were estimated using commerially available kits (Boheringer, Mann.eim, Germany). VLDL and LDL were isolated by precipitations with a mixture of phosphotungstic acid and magnesium ions. After standing for 10 min at room temper e the mixtures were centrifuged at 10 000 g for 10 min, the supernatant containing the HDL fraction was removed and the levels of choleterol, triglyceride and phospholipid were determined. The precpitate containing the VLDL-LDL fraction was dissolved in 0.15 M sodium chloride and the cholsterol, triglycerides and phospholipids were assayed as above.
Statistical analysis
Significance of the differences was caculated by the Student's t-test.
Rc6
The ascites hepatoma Yoshida AH-130 caused a loss of body weight in tumour hosts, in assocation with the presene of detctable levels in circulating TNF. A decrease in daily food intake was also observed in tumour-bearing rats (Table I) .
The results are in agreement with our previous studies which have d onstrated that ascites hepatoma AH-130 causes in the rat host a pd and progre loss of body weight, a progressivedecline of food intake, skeletal muscle waste and ipid depletion Carb6 et al., 1994) . The anti-TNF treatment effectively neuralsed circulating TNF, while neither the anti-TNF antibodies nor non-immune IgGs modified tumour growth, body weight loss and food intake dedine (Table I) .
The hepatic synthesis of total choksterol and triglyrides is shown in Table HI . The synthesis of total choleterol was reduced during tumour growth, while no changes were obsrved for triglycides, in keeping with previous observations and were not modified by the anti-TNF treatment (Table III) . Consitently, total and free cholesterol and tiglyceride levels in tumour cells
were not affected by the treatment (Table IV) . Moreover, anti-TNF administration did not change the intracellular content of phospholipids or protein (Table IV) .
The lipid and protein content of whole serum collected from control and tumour-bearing rats receiving anti-TNF or not is presented in Table V . While plasma protein is dreased nearly 20% in AH-130-bearing animals, the lvels of all lipid classes, except phospholiids are elevated, particularly free fatty acids and triglycerides. Trigykeride and free fatty acid levels were reduced, at least in part, by anti-TNF administration. Likewise, the anti-TNF treant prevented the decrease in serum protein concentration, which is consistent with its effectiveness in preventing tissue protein hypercatabolism . By contrast the above parameters were not modified when the animals were given the non-immune IgGs (Table V) .
In the untreated tumour hosts both the protein and lipid constituents of the HDL lipoprotein fraction were decreased, with the exception of triglycerides, whose levels inreased 3-4-fold with respect to controls (Table VI; see . The anti-TNF treatment was able to correct the reduced protein content only (Table VI) . By contrast, all the constituents were inreased in the VLDL-LDL fraction of untreated AH-130 bearers with respect to controls Anti-TNF antibodie reduced, at least in part, the elevation of triglycenides (Table VII) . Non-immune IgGs genrally did not affect the parameers analysed in both the HDL and VLDL-LDL fractions, with the exception of triglycerides in the latter (Table VII) .
Consistent with the results obtained using precipitation methods, the analysis of plasma lipoproteins by HPLC revaled an elevation of VLDL-LDL in host rats compared with controls (Figure la and b) . In contrast HDL2, normally the main lipoprotein subfraction in rat serum was strongly reduced. (Figue lb) . An increase in the HDL3 subfraction was also evident in AH-130 tumour-bearing rats (Figure lb) . Anti-TNF treatment was able to reduce both VLDL and LDL fraction in AH-130-bearing rats, while in these animals HDL2 remains below the normal values (Figure ld) . IgGs did not affect greatly lipoprotein profiles observed in tumourbearing rats (Figure lc) .
Fmally, the anti-TNF treatment did not modify the lipid and protein composition in the ascitic fluid (data not shown).
Previous studies by our laboratories Changes in lipid metabolism are a common feature during neoplastic growth, both in humans and in different experimental model systems (Clark and Crain, 1986; Dessi et al., 1986 Dessi et al., , 1989 Dessi et al., ,b, 1994 . However, the mechanisms underlying these changes are stfill unclear and complicated by the fact that the metabolic alterations are species specific and dependent on the histological type or the degree of malignancy.
In this report, our results on serum cholesterol and lipoprotein levels in tumour-bearing rats were similar to those previously observed by other investigators in rats and mice (Kannan and Baker, 1977; Clark and Crain, 1986) , but in contrast with those reported in humans (Rossner and Wallgren, 1984; Vitols et al., 1985; Bani et al., 1986; Reverter et al., 1988; Dessi et al., 1991 Dessi et al., , 1992b Dessi et al., , 1994 . In particular, normal or decreased serum cholsterol levels were observed in cancer patients, while triglyceridaemia appears variable, dependent on the type of tumours and age of appearance.
Nevertheless, a decrease in crculating HDL levels is found in virtually all neoplastic and inflammatory diseases studied in both rodents and humans (Dessi et al., 1986 (Dessi et al., , 1989 (Dessi et al., , 1991 (Dessi et al., ,b, 1994 Feingold et al., 1993) suggesting that the mechanisms underlying changes in total cholesterolaemia and triglycerilaemia are presumably different from those responsible for lowering HDL levels.
Based on our data, two mechanisms can be considered to explain the increase in circulating lipids in AH-130 hosts. First, an increased moblisation of lipids from fat depots, as evidenced by the loss of body weight and the increase in serum free fatty acids. Second, a decrease in the clarance of VLDL as evidenced by the decrease in LPL activity in adipose tissue previously observed in this type of tumour (Carbo et al., 1994) . Under our experimental conditions, it is unlikely that diet and endogenous biosynthesis can be responsible for the observed hyperlipidaemia in that both hepatic lipid synthesis and food intake, the two main sources of plasma lipids in the body, were normal or decreased in tumour-bearing rats.
TNF, a pleiotropic cytokine, is primarily produced by activated macrophages in response to invasive stiuli (Beutler and Cerami, 1988 Values are mean ± s.e.m. aMeans with the same letter are not significantly different. lipogenesis, resulting in increased concentrations of circulating lipids (Feingold and Grunfeld, 1987; Starnes et al.. 1988; Evans et al., 1989; Grunfeld et al., 1989 (Feingold and Grunfeld, 1987 ).
These observations support the conclusion that TNF may be involved in the alterations of lipid metabolism that affect the AH-130 tumour bearers (Carbo et al., 1994) . However, treatment with anti-TNF only partially corrected tumourinduced perturbations of lipid metabolism. In particular, triglyceridaemia and free fatty acid levels were reduced, while anti-TNF treatment did not affect total cholesterolaemia and HDL levels.
Cell proliferation, either normal or neoplastic, is commonly associated with altered cholesterol metabolism, and in particular with decreased plasma HDL-cholesterol levels (Dessi et al., 1986 (Dessi et al., , 1989 (Dessi et al., , 1992b . It has been proposed that this reduction results from a decrease in the release of cholesterol from proliferating cells to HDL (Daniels et al., 1987) . Exogenous cholesterol and cell growth rate modulate the activity of specific HDL receptors; the binding with HDL promotes selective removal of excess cholesterol from the intracellular pool (Oram et al., 1987) . It has been shown that both HDL-mediated efflux and HDL receptor activity are down-regulated in actively proliferating cells (Bierman et al., 1989) , likely resulting in the reduction of HDL-cholesterol plasma levels.
In the present paper we demonstrate that the anti-TNF treatment is unable to either modify the growth rate of the AH-130 hepatoma or to prevent the decrease in plasma HDL-cholesterol, further supporting the existence of a close relationship between these two parameters. On the whole, these observations suggest that the hypertriglyceridaemia and the increase of VLDL and LDL, and the increase of HDL metabolism in rats bearing the AH-130 tumour are regulated, at least in part, by different mechanisms. Decreased LPL activity mediated by TNF could well account for the former. By contrast, TNF does not appear to be directly involved in the perturbations of HDL metabolism, which seem to be strictly related to tumour proliferation rates.
